Patent · US Active

Insulin conjugates

US11098102B2 · kind B2 · utility

1Cited by

1References

24Claims

0Family size

Assignee

Sanofi · FR

Inventors

Maria MENDEZ PEREZ · Frankfurt am Main, DE
Nils RACKELMANN · Frankfurt am Main, DE
Laurent Bialy · Frankfurt am Main, DE
Stefan Guessregen · Frankfurt am Main, DE
Martin Will · Frankfurt am Main, DE
Thomas Boehme · Gerolzhofen, DE
Ana VILLAR GAREA · Frankfurt am Main, DE
Marcus Hermann KORN · Offenbach, DE
Melissa BESENIUS · Frankfurt am Main, DE
Jens RIEDEL · Frankfurt am Main, DE
Ulrich Werner · Frankfurt am Main, DE
Michael PODESCHWA · Frankfurt am Main, DE

Key dates

Filing date	Dec 10, 2019
Grant date	Aug 24, 2021
Priority date	—
Expiry date	Dec 10, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/64
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.